Anticorps Monoclonal anti-IGFBP6

IGFBP6 Monoclonal Antibody for FC (Intra)

Hôte / Isotype

Mouse / IgG2b

Réactivité testée

Humain

Applications

FC (Intra)

Conjugaison

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

1D12B3

N° de cat : CL488-67567

Synonymes

IBP 6, IBP6, IGF binding protein 6, IGFBP 6, IGFBP6

---

Galerie de données de validation

• 

  FC experiment of A431 using CL488-67567

  1X10^6 A431 cells were intracellularly stained with 0.4 ug CoraLite® Plus 488 Anti-Human IGFBP6 (CL488-67567, Clone:1D12B3) (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

---

Applications testées

• Résultats positifs en cytométrie: cellules A431

Dilution recommandée

• Flow Cytometry (FC): FC : 0.40 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Informations sur le produit

CL488-67567 cible IGFBP6 dans les applications de FC (Intra) et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Mouse / IgG2b
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: IGFBP6 Protéine recombinante Ag30050
• Nom complet: insulin-like growth factor binding protein 6
• Masse moléculaire calculée: 25 kDa
• Poids moléculaire observé: 30-33 kDa
• Numéro d’acquisition GenBank: BC011708
• Symbole du gène: IGFBP6
• Identification du gène (NCBI): 3489
• Conjugaison: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 493 nm / 522 nm
• Forme: Liquide
• Méthode de purification: Purification par protéine A
• Tampon de stockage: PBS avec glycérol à 50 %, Proclin300 à 0,05 % et BSA à 0,5 %, pH 7,3.
• Conditions de stockage: Stocker à -20 °C. Éviter toute exposition à la lumière. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Insulin-like growth factor (IGF) binding protein (IGFBP6), a 240 amino acid protein, contains an IGFBP N-terminal domain and a thyroglobulin type-1 domain. It modulates the activity of IGF and shows independent effects of IGF, such as growth inhibition and apoptosis. It can decrease the proliferation and survival of cancer cells such as lung cancer cells and naso-pharyngeal cancer cells. IGFBP-6 is distinctive for its 50-fold higher binding affinity for IGF-II over IGF-I and this specificity makes it an attractive potential therapeutic candidate for IGF-II-dependent pediatric malignancies such as rhabdomyosarcoma (RMS). In addition, it was found that IGFBP6 can promote the migration of RMS cells in an IGF-independent manner, and MAPK pathways were involved in this process. Further study reported that IGFBP6 is one of most highly expressed proteins in varicose vein tissues and is involved in the proliferation of vascular smooth muscle cells (VSMCs), which may provide insights into the underlying pathogenesis of varicose vein.